Prothrombin Complex Concentrate Market Size
:
Prothrombin Complex Concentrate size was USD 727.5 million in 2021 and projected to grow from USD 883.9 million in 2023 to USD 2153.2 million by 2032, exhibiting a CAGR of 10.4% during the forecast period.
Prothrombin Complex Concentrate (PCC) is also known as factor lX complex, which is a medicament created using blood clotting factors ll, lX, and X which helps in the treatment of bleeding disorders. Few versions of PCC even contain factor Vll. PCC is obtained from human plasma and contains concentrated coagulation factors. It is utilized to resolve and prevent bleeding in haemophilia B and is used in insufficiency of these components due to warfarin treatment etc. It is incorporated into the body using a syringe into vein. By administering through IV, PCC refillls the coagulation factors in the blood immediately.
Market Highlights
Prothrombin Complex Concentrate Market is expected to project a CAGR of 10.4% during the forecast period, 2022-2032
Prothrombin Complex Concentrate Market is expected to reach USD 2153.2 million, growing at a CAGR of 10.4% during forecast period. Prothrombin Complex Concentrate (PCC) is anticipated to increase due to the presence of several clinical advantages over fresh frozen plasma (FPP). PCC take less volume and time to infuse compared with FPP and is efficient. PCC has no requirement for blood matching and thawing which increases the preference and demand for PCC market growth. The relaxation of government regulations and policies have created positive impact for the growth of the PCC market.
Prothrombin Complex Concentrate Market Segmentation:
3-Factor PCC segment is expected to grow with high CAGR during the forecast period
Prothrombin Complex Concentrate Market is classified based on the Product into 3-Factor PCC, 4-Factor PCC. The 4-factor segment dominated the market in 2021 owing to the enhanced penetration of 4-factor PCC in developing countries and their efficacy for warfarin reversal which helped to boost the growth of the market. The government initiatives to reduce adverse events related to warfarin is anticipated to boost the growth of segment. The 3-factor segment is expected to dominate the market in the forecast period owing to the increasing prevalence of haemophilia and growing demand for plasma products which is expected to drive the segment growth.
Specialty clinics segment are expected to grow with high CAGR during the forecast period
Prothrombin Complex Concentrate Market is classified based on the End-Use into Hospitals, Ambulatory Surgical Centres, Specialty Clinics and Others. The hospitals segment dominated the market in 2021 owing to the increasing preference for prothrombin complex concentrate, favourable government initiatives, and increased obtaining of plasma products. Specialty clinics segment is anticipated to grow in forecast period due to the growing surgeons and increasing number of privately-owned clinics.
Market Dynamics:
Growth Drivers
Growing Haemophilia B Issues is Expected to Boost the Growth of the Market
The growing prevalence of Haemophilia B is expected to boost the growth of the market. The initiation of different kinds of Vitamin K antagonist products is expected to increase the usage of Prothrombin Complex Concentrate. The use of warfarin has increased which is expected to boost the market growth. The positive government regulations and norms for the use of factor IX complex for warfarin reversal is expected to boost the market growth. The increased incidence of bleeding disorders has also created growth option for the Prothrombin Complex Concentrate market.
Advantages of Prothrombin Complex Concentrate May Boost the Market Growth
PCC possess several advantages over many other alternatives like Vitamin K1, FFP etc., which is responsible for usage in urgent warfarin-reversals. PCC has minimal risk of viral transmission. PCC removes the necessity of blood matching & thawing, unlike FFP and it provide less penetration time with high efficiency and require less volume which may boost the growth of the Prothrombin Complex Concentrate market. Increasing surgeries requiring the need of PCC may also boost the market as the surgical procedures have necessity to manage coagulation disorders.
Restraint
High Procurement Cost May Restrain the Growth of the Market
The high rate of competition and growing procurement costs may restrain the growth of PCC market in the forecast period. The thrombotic complications which might arise from the use of PCC may also restrain the growth of the market.
Recent Developments:
- In March 2019, Grifols S.A. had an agreement with Shanghai RAAS in interchanging for non-minority share in Grifols Diagnostic Solutions.
- In January 2019, Grifols S.A. obtained Biotest Pharmaceuticals Corporation, US branch to improve its presence in North America.
Prothrombin Complex Concentrate Market
Key Players Covered:
- Octapharma AG
- Grifols S.A.
- Novo Nordisk
- CSL Behring GmbH
- Kedrion Biopharma Inc.
- China Biologic Products Holdings, Inc.
- Shire Plc
- Sanquin
- Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)
Regional Analysis
Prothrombin Complex Concentrate Market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. North America dominated the market in 2021 owing to the presence of key market players, increasing demand for PCC which created demand for growth of the market in the region. Asia Pacific region is expected to dominate the market in the forecast period owing to the increasing use of number of patients and government initiatives to improve the therapies which is expected to boost the growth of the Prothrombin Complex Concentrate Market.
Impact of Covid-19 on Prothrombin Complex Concentrate Market
The COVID-19 outbreak had resulted in the downfall of economies worldwide. Several countries had imposed lockdowns and applied travel restrictions to control the spread of the virus. Due to the restrictions imposed, there was improper connectivity which led to disruptions in the supply of PCC and blood-derivatives but pandemic created requirement for PCC. Covid-19 pandemic, in total had slight positive impact for the growth of the market.
Prothrombin Complex Concentrate Market is further segmented by region into:
- North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
- Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
- Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
- Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC
- Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA.
Prothrombin Complex Concentrate Market Scope and Segments:
|
ATTRIBUTE |
DETAILS |
|
Study Period |
2018-2032 |
|
Base Year |
2022 |
|
Forecast Period |
2021-2032 |
|
Historical Period |
2019-2021 |
|
Growth Rate |
CAGR of 10.4% from 2022-2032 |
|
Unit |
Value (USD Million) |
|
Segmentation |
Main Segments List |
|
Product |
|
|
Application |
|
|
End-Use |
|
|
By Region |
|
.png){kind=icon}
